🇺🇸 FDA

Intelligence · Patent portfolio

NORTHWEST BIOTHERAPEUTICS Patents

Full USPTO pharma patent portfolio for NORTHWEST BIOTHERAPEUTICS — grant dates, expiration, and drug cross-links.

Patents
595
Expiring ≤24m
13

Quick answer

NORTHWEST BIOTHERAPEUTICS has 595 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 13 expire within 24 months — use filters for patent-cliff planning.

Page 4 of 13

  1. US 11241478

    Adenovirus-associated viral vectors for expressing variants of tetratricopeptide repeat (TPR)-containing Rab8b interacting (TRIP8b) protein in neurons and uses thereof for treating major depressive disorder (MDD)

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11225483

    Substituted fused pyrrolo-diazepinones and uses thereof

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11219608

    Triple combination formulation for treatment of chronic pain

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11213593

    Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11207283

    Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11207423

    Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11203596

    Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11202823

    Multi-subunit vaccines to elicit both MHC- and CD1-restricted T cell responses

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11191842

    Injectable thermoresponsive polyelectrolytes

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11185674

    Targeted delivery of biologic therapeutic agents

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11179494

    Collagenous tissue repair device

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11174514

    Methods, kits, and devices utilizing HTR2C polymorphisms for diagnosing, prognosing, and treating psychiatric disorders in a patient

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11174288

    Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11160851

    Peptide conjugated particles

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11161876

    Anti-inflammatory nanofibers

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11149020

    MAP kinase modulators and uses thereof

    Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11142504

    Substituted heterocycles as c-MYC targeting agents

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11135236

    Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11129881

    Peptide conjugated particles

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11129790

    Chemo-enzymatic site-specific modification of peptides and proteins to form cleavable conjugates

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11124768

    Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11125741

    Compositions and methods for the detection of zinc

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11124612

    Facile assembly of soft nanoarchitectures and co-loading of hydrophilic and hydrophobic molecules via flash nanoprecipitation

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11118180

    Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11110139

    Application of anthocyanin extract in preparing pharmaceutical composition for preventing and treating cardiac toxicity induced by anthracyclines and pharmaceutical composition

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11104901

    Brush polymer-assisted compaction of oligonucleotides

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11078471

    Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11077057

    Polymer-grafted nanobins

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11071727

    Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11066444

    BMP-2-binding peptide amphiphile nanofibers

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11065299

    Compositions and methods for modulation of immune response

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11065262

    Topical treatment of wounds with statins and cholesterol for scar reduction

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11059878

    Therapeutic targeting of SET1B/compass pathway for treating cancers

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11041205

    Molecular targets for ALS and related disorders

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11033541

    Epimorphic regeneration and related hydrogel delivery systems

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11021435

    Serotonin receptor-targeting compounds and methods

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11001618

    Overexpression of FOXC1 to treat corneal vascularization

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10994016

    Graphene oxide mediated cellular delivery of gadolinium-labeled molecules

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10967072

    Short interfering RNA templated lipoprotein particles (siRNA-TLP)

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10968206

    Cannabinergic nitrate esters and related analogs

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10934270

    Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10934547

    Use of trinucleotide repeat RNAs to treat cancer

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10906913

    NMDA receptor modulators and uses thereof

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10874610

    Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10835604

    Biomaterials for combined radiotherapy and immunotherapy of cancer

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10829795

    Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10829752

    Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10821078

    Nanostructure enhanced targeting (NSET) of inflammatory cells

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does NORTHWEST BIOTHERAPEUTICS have?

595 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do NORTHWEST BIOTHERAPEUTICS patents expire?

13 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.